S. Vongpunsawad

Dr. S. Vongpunsawad


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
JPJiratchaya Puenpa
Jiratchaya Puenpa
NWNasamon Wanlapakorn
Nasamon Wanlapakorn
SVS. Vongpunsawad
S. Vongpunsawad
YPYong Poovorawan
Yong Poovorawan
Enterovirus A71 (EV-A71) is one of the common causative pathogens for hand foot and mouth disease (HFMD) affecting young children. HFMD outbreak can result in a substantial pediatric hospitalization and burden the healthcare services, especially in less-developed countries. Since the initial epidemic of predominantly EV-A71 in California in 1969, the high prevalence of HFMD in the Asia-pacific region and elsewhere around the world represents a significant morbidity in this age group. With the advent of rapid and accurate diagnostic tools, there has been a dramatic increase in the number of laboratory-confirmed EV-A71 infection over the past two decades. The population, cultural, and socioeconomic diversity among countries in the Asia-Pacific region all influence the transmission and morbidity associated with HFMD. This review summarizes the current state of epidemiology of EV-A71 in Asia-Pacific countries based on the most recent epidemiological data and available information on the prevalence and disease burden. This knowledge is important in guiding the prevention, control and future research on vaccine development of this highly contagious disease of significant socioeconomic implications in public health.

5 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RWRujipat Wasitthankasem
Rujipat Wasitthankasem
PVPreeyaporn Vichaiwattana
Preeyaporn Vichaiwattana
NSNipaporn Siripon
Nipaporn Siripon
NPNawarat Posuwan
Nawarat Posuwan
CAChompoonut Auphimai
Chompoonut Auphimai
YPYong Poovorawan
Yong Poovorawan
Improved awareness of the hepatitis C virus (HCV) transmission has contributed to the overall decline in the HCV infection rate in some developing countries including Thailand. Chronic HCV infection in some rural Thai communities, however, presents a challenge in the efforts to treat and manage HCV-related diseases. Published and unpublished studies have suggested an unusually high incidence of HCV infection in a Thai province of Phetchabun compared to elsewhere in Thailand. To determine the magnitude of HCV infection and identify potential factors contributing to the higher rate of HCV infection in this province, we performed a population-based study in Phetchabun (n = 1667) and the neighboring Khon Kaen province (n = 1410) where HCV prevalence is much lower. Individuals between 30 and 64 years old completed detailed questionnaires designed to identify HCV risk factors and provided blood samples for anti-HCV antibody screening. The anti-HCV seropositive rates were 15.5% (259/1667) in Phetchabun and 3.6% (51/1410) in Khon Kaen. Positive samples were subsequently genotyped for HCV core gene sequence and assessed for the hepatitis B virus surface antigen (HBsAg) and human immunodeficiency virus antigen/antibody (HIV Ag/Ab). More individuals in Phetchabun possessed the combined presence of HBsAg (5.0%) and HIV Ag/Ab (0.4%) than those in Khon Kaen (3.9% HBsAg and 0.0% HIV Ag/Ab). While male gender, intravenous drug use (IVDU) and tattoos were significant HCV risk factors in both provinces (p <0.05), education less than high school and agriculture-related occupation were additionally associated with HCV in Phetchabun. HCV genotypes 6, 3, and 1 were identified in similar frequency in both provinces. We estimated that prevalence of HCV seropositivity and viremic carriers were higher in Phetchabun (143 and 111 per 1000) than in Khon Kaen (34 and 22 per 1000). Finally, we derived a simple risk factor-based scoring system as a useful preclinical tool to screen individuals at risk of chronic HCV infection prior to intervention. Knowledge gained from this study will assist in HCV screening and promote access to anti-viral treatment in high-risk groups.

8 July 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
RWRujipat Wasitthankasem
Rujipat Wasitthankasem
NPNapaporn Pimsingh
Napaporn Pimsingh
KTKhuandao Treesun
Khuandao Treesun
NPNawarat Posuwan
Nawarat Posuwan
PVPreeyaporn Vichaiwattana
Preeyaporn Vichaiwattana
YPYong Poovorawan
Yong Poovorawan
Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and hepatocellular carcinoma. To eliminate HCV infection in an endemic area, an epidemiological baseline of the current HCV infection in the population is required. We therefore aimed to evaluate the HCV burden in the Thai Province of Phetchabun, which has the highest HCV infection rate in the country. Toward this, a province-wide district-based representative sampling of 4,769 individuals ages 35–64 years previously shown to represent high-risk age-groups were tested for anti-HCV antibodies using the automated chemiluminescent microparticle assays. Active HCV infection and subsequent genotyping were determined from serologically reactive samples by amplification of the HCV core gene. We found that 6.9% (327/4,769) were anti-HCV positive, of which 75.8% (248/327) had detectable HCV RNA and 5.8% (19/327) were in the presence of hepatitis B virus coinfection. Nucleotide sequencing and phylogenetic analysis revealed that HCV genotype 6 was the most prevalent (41%, 101/248), followed by genotype 3 (31%, 78/248), and genotype 1 (28%, 69/248). Socioeconomic and demographic factors including male gender, education, and agricultural work were associated with HCV seropositivity. From these results, we defined the regional HCV genotypes and estimated the HCV burden necessary toward the implementation of pan-genotypic direct-acting antivirals, which may be appropriate and effective toward the diversity of genotypes identified in this study. Micro-elimination of HCV in Phetchabun may serve as a model for a more comprehensive coverage of HCV treatment in Thailand.

29 July 2015 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
TPTikumporn Phumpholsup
Tikumporn Phumpholsup
TCThaweesak Chieochansin
Thaweesak Chieochansin
SVS. Vongpunsawad
S. Vongpunsawad
VVViboonsuk Vuthitanachot
Viboonsuk Vuthitanachot
SPSunchai Payungporn
Sunchai Payungporn
YPYong Poovorawan
Yong Poovorawan

3 January 2023 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
FLFajar Budi Lestari
Fajar Budi Lestari
KCKirkvich Chandranoi
Kirkvich Chandranoi
WCWatchaporn Chuchaona
Watchaporn Chuchaona
SVS. Vongpunsawad
S. Vongpunsawad
YPYong Poovorawan
Yong Poovorawan

13 October 2023 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
PRPatthaya Rattanakomol
Patthaya Rattanakomol
SKSarawut Khongwichit
Sarawut Khongwichit
WCWatchaporn Chuchaona
Watchaporn Chuchaona
SVS. Vongpunsawad
S. Vongpunsawad
YPYong Poovorawan
Yong Poovorawan